Search | Clinical Trials Finder

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 11:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 3289–3312 of 22,018 matching trials from the local directory fallback.

Filters: Recruiting Clear all

Conditions: Needle Phobia
Interventions: 1% Lidocaine Skin Wheal, Lidocaine patch 4%, Placebo Patch; Drug · Other
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Localized Breast Carcinoma
Interventions: Best Practice, Patient Navigation, Referral, Survey Administration; Other · Behavioral
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Phenylketonuria (PKU)
Interventions: MZE782, Placebo; Drug · Other
Lead sponsor: Maze Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Oakland, California • Palo Alto, California • Chicago, Illinois + 4 more

Conditions: Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC)
Interventions: Carboplatin, Cisplatin, Imzokitug, Paclitaxel, Pemetrexed, Pumitamig; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 12
States / cities: Washington D.C., District of Columbia • Athens, Georgia • Lexington, Kentucky + 8 more

Conditions: Acute Compartment Syndrome, Proximal Tibia Fracture, Tibial Shaft Fracture
Interventions: Continuous Compartmental Pressure Monitor; Device
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 10 Years to 21 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: Partial Breast Irradiation; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 40 Years to 85 Years · Female only
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2036
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Interventions: Placebo, WIN378; Drug
Lead sponsor: Windward Bio; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 9
States / cities: Los Angeles, California • Jacksonville, Florida • Miami Lakes, Florida + 6 more

Conditions: Spinal Cord Injury
Interventions: Control diet, Sitz Marker Test, fermented foods; Other · Device
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Lipoprotein(a)
Interventions: Enlicitide, MK-7262, Placebo for MK-7262, Placebo for enlicitide; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 24
States / cities: Alexander City, Alabama • Mobile, Alabama • Beverly Hills, California + 21 more

Conditions: Acellular Dermal Matrix, Bone Grafting, Soft Tissue Grafting
Interventions: Guided Bone Regeneration with ADM (AlloDerm) as a barrier, Guided Bone Regeneration with Resorbable Crosslinked Collagen Matrix (Mem-Lok) as a barrier; Procedure
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 85 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: 3'-Deoxy-3'-[18F]-fluorothymidine, Chemical-shift-encoded MRI; Drug · Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Gastrointestinal Stromal Neoplasms
Interventions: Imatinib, Velzatinib; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 12
States / cities: Scottsdale, Arizona • San Francisco, California • New Haven, Connecticut + 9 more

Conditions: Paroxysmal Atrial Fibrillation (PAF), Persistent Atrial Fibrillation
Interventions: FARAFLEX Mapping and Pulsed Field Ablation (PFA) System; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 571 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 10
States / cities: Jonesboro, Arkansas • Atlanta, Georgia • West Des Moines, Iowa + 7 more

Conditions: Metastatic Castration-resistant Prostate Cancer (mCRPC)
Interventions: Abiraterone, Androgen deprivation therapy (ADT), Enzalutamide, INR731; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Boston, Massachusetts • Dallas, Texas

Conditions: Diabetic Retinal Disease
Interventions: Anti-Vascular Endothelial Growth Factor; Drug
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 8
States / cities: Huntington Beach, California • Augusta, Georgia • Boston, Massachusetts + 5 more

Conditions: Pregnancy Related
Interventions: Elafibranor; Drug
Lead sponsor: Ipsen; Industry
Eligibility: Female only
Enrollment: 3 participants
Timeline: 2026 – 2039
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma, IDH-Wildtype
Interventions: Autologous Anti-EGFR/Anti-IL13Ralpha2 CAR T-cells, Biopsy Procedure, Biospecimen Collection, Echocardiography Test, FDG-Positron Emission Tomography, Intracranial Catheter Placement, Leukapheresis, Magnetic Resonance Imaging, Resection; Biological · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Duarte, California

Conditions: Prostate Cancer
Interventions: High-Intensity Interval Training (HIIT) Exercise; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Cognitive Complaint, Cognitive Dysfunction, Neurocognitive Function, Psychosocial Well-being
Interventions: Computerized Cognitive Training, taVNS; Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 45 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Amputation
Interventions: Prosthetic socket fit testing system; Device
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Colitis Ulcerative, Ulcerative Colitis
Interventions: MK-8690, Placebo; Drug · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 11
States / cities: Anaheim, California • Coronado, California • Colorado Springs, Colorado + 8 more

Conditions: Atopic Dermatitis (AD), Eczema
Interventions: ARQ-234, Placebo; Biological · Drug
Lead sponsor: Arcutis Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Miami, Florida • Plainfield, Indiana • Fair Lawn, New Jersey + 3 more

Conditions: Plaque Psoriasis
Interventions: ORKA-001; Drug
Lead sponsor: Oruka Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 26
States / cities: Phoenix, Arizona • North Little Rock, Arkansas • Fountain Valley, California + 20 more

Conditions: Pancreatic Cancer
Interventions: AG [gemcitabine+nab-paclitaxel], ANO31905, mFOLFIRINOX [Oxaliplatin+irinotecan+leucovorin+fluorouracil]; Drug
Lead sponsor: Anova Innovation Limited; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Los Angeles, California • Plantation, Florida • San Antonio, Texas

Search by objective public record fields.

Lidocaine Patch for Epidural Placement Pain in Laboring Women

A Navigation Program to Improve Survivorship Support Service Participation Among Non-metastatic Breast Cancer Survivors

A Study of MZE782 in Adults With PKU

A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

MY01 Pressure Monitoring in Adolescent Tibia Fractures

Single FrAction Interstitial BreaSt BracHytherApy

A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)

Fermented Foods and Bowel Health in SCI

A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)

Evaluating the Barrier Function, Regenerative Capacity, and Soft Tissue Outcomes of Acellular Dermal Matrix

Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical Therapy

A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)

Evaluation of the FARAFLEX Mapping and Pulsed Field Ablation System in Subjects With Atrial Fibrillation

A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer

Longitudinal Study of Retinal Function in Eyes Treated for Diabetic Macular Edema With Anti-VEGF Agents

Elafibranor Pregnancy Surveillance Program: A Study to Evaluate the Safety of Elafibranor During Pregnancy

Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas

Exercise-induced Steroid Changes in Active Surveillance for Prostate Cancer

taVNS + CCT for Neurocognitive Rehab

Prosthetic Socket Fit Testing System

A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)

Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer